| Name | Aripiprazole Lauroxil |
| Description | Aripiprazole lauroxil, the N-acyloxymethyl prodrug form of aripiprazole, a long-acting injectable (LAI) antipsychotic. Aripiprazole lauroxil is cleaved by esterases in vivo to N-hydroxymethyl aripiprazole (lauric acid), which is then cleaved to aripiprazole, which is non-toxic. |
| In vivo | Intravenous administration of 1.87?mg/ml Aripiprazole lauroxil bioconversion in vivo involves the formation of an intermediate,?N-hydroxymethyl aripiprazole. The?in vitro?data indicates a high bioconversion of aripiprazole lauroxil, thus, the concentration of?N-hydroxymethyl aripiprazole observed in the animals dosed with aripiprazole lauroxil is surprisingly high[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 0.5 mg/mL (0.76 mM), Sonication is recommended. DMSO : 8 mg/mL (12.11 mM), Sonication is recommended.
|
| Keywords | schizophrenia | Inhibitor | inhibit | DopamineReceptor | Dopamine Receptor | D2 receptor | Aristada | Aripiprazole Lauroxil | 5HTReceptor | 5-HT2A | 5-HT1A | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Cefaclor monohydrate | Hexamethonium Bromide | Octopamine hydrochloride | 1,8-Cineole | L-DOPA | Creatine | Oxolinic acid | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Serotonin Receptor-Targeted Compound Library | Anti-Cancer Drug Library |